Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2017 by Dana-Farber Cancer Institute
Sponsor:
Information provided by (Responsible Party):
Beth Overmoyer, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01796197
First received: February 20, 2013
Last updated: April 27, 2017
Last verified: April 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2020
  Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)